Global Pegfilgrastim Biosimilars Market Report and Forecast 2023-2031
Global Pegfilgrastim Biosimilars Market Outlook
The global pegfilgrastim biosimilars market size was valued at USD 0.54 million in 2022 and is projected to grow at a CAGR of 7% during the forecast period of 2023-2031. The market growth can be attributed to the increasing prevalence of cancer, a growing geriatric population, and the rising demand for affordable cancer therapies.
Global Pegfilgrastim Biosimilars Market: Introduction
Pegfilgrastim biosimilars are biologically similar versions of the reference pegfilgrastim product, which is used to stimulate the growth of white blood cells to help reduce the risk of infection during cancer treatment. These biosimilars have demonstrated comparable safety and efficacy to the reference product but are typically available at a lower cost, making them an attractive option for healthcare systems and patients. The increasing prevalence of cancer, coupled with the growing demand for cost-effective cancer treatments, is driving the demand for pegfilgrastim biosimilars. Other factors, such as the expiration of key patents and the development of robust regulatory frameworks, are also expected to drive market growth.
Pegfilgrastim Biosimilars Market Segmentations
The market can be segmented based on indication, product type, application, distribution channel, and region:
Market Breakup by Indication Type
- Neutropenia
- Hematopoietic Subsyndrome
- Others
- MK-6302
- Peg G-CSF
- PEG Neutrogena
- Grasustek
- LA-EP2006
- R-TPR-029
- Filgrastim
- PEG-GCSF
- Others
- Chemotherapy Induced Neutropenia
- Transplantation
- Others
- Hospital Based Pharmacies
- Online Pharmacies
- Retail Pharmacies
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
The global pegfilgrastim biosimilars market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of cancer, the growing geriatric population, and the rising demand for cost-effective cancer therapies. North America is currently the largest market for pegfilgrastim biosimilars, driven by factors such as the high prevalence of cancer, a well-established healthcare infrastructure, and strong investments in research and development. Additionally, the growing adoption of biosimilars and supportive regulatory frameworks are further driving the growth of the market in North America.
Asia Pacific is another region experiencing significant growth in the pegfilgrastim biosimilars market. The region's market growth is driven by factors such as a large population base, increasing cancer incidence, and growing healthcare expenditure. In addition, government initiatives to improve healthcare infrastructure and support the development of biosimilars are helping to drive the growth of the market in the region.
Key Players in the Global Pegfilgrastim Biosimilars Market
The report provides a detailed analysis of the key players involved in the pegfilgrastim biosimilars market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
- Merck & Co., Inc.
- Zydus Lifesciences Limited
- Ratiopharm GmbH
- Jiangsu Hengrui Pharmaceuticals Co. Ltd
- Biocon Limited
- Dr. Reddy's Laboratories Ltd
- Pfizer Inc.
- Emcure Pharmaceuticals Limited
- USV Private Limited
- Apotex Pty Ltd
- Kyowa Kirin Co., Ltd.
- Lupin Limited
*Please Note:* The report will be completed in 7 business days after order confirmation
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 2 Research Methodology
- 3 Executive Summary
- 4 Pegfilgrastim Biosimilars Overview
- 4.1 Drug Overview
- 4.1.1 Pharmacodynamics
- 4.1.2 Pharmacokinetics
- 4.1.3 Adverse Events
- 5 Patient Profile
- 5.1 Patient Profile Overview
- 5.2 Patient Psychology and Emotional Impact Factors
- 5.3 Risk Assessment and Treatment Success Rate
- 6 Current Scenario Evaluation and Regulatory Framework
- 6.1 Emerging Therapies and Clinical Trials Synopsis
- 6.2 Patent Landscape
- 6.2.1 Patent Overview
- 6.2.1.1 Patent Status and Expiry
- 6.2.1.2 Timelines from Drug Development to Commercial Launch
- 6.2.1.3 New Drug Application
- 6.2.1.3.1 Documentation and Approval Process
- 6.3 Cost of Treatment
- 6.4 Investment Scenarios
- 6.5 Regulatory Framework
- 6.5.1 Regulatory Overview
- 6.5.1.1 US FDA
- 6.5.1.2 EU EMA
- 6.5.1.3 INDIA CDSCO
- 6.5.1.4 JAPAN PMDA
- 6.5.1.5 Others
- 7 Challenges and Unmet Needs
- 7.1 Treatment Pathway Challenges
- 7.2 Compliance and Drop-Out Analysis
- 7.3 Awareness and Prevention Gaps
- 8 Global Pegfilgrastim Biosimilars Market
- 8.1 Global Pegfilgrastim Biosimilars Market Overview
- 8.2 Global Pegfilgrastim Biosimilars Market Analysis
- 8.2.1 Market Overview
- 8.2.1.1 Global Pegfilgrastim Biosimilars Market Historical Value (2016-2022)
- 8.2.1.2 Global Pegfilgrastim Biosimilars Market Forecast Value (2023-2031)
- 8.3 Global Pegfilgrastim Biosimilars Market by Indication Type
- 8.3.1 Market Overview
- 8.3.1.1 Neutropenia
- 8.3.1.2 Hematopoietic Subsyndrome
- 8.3.1.3 Others
- 8.4 Global Pegfilgrastim Biosimilars Market by Product Type
- 8.4.1 Market Overview
- 8.4.1.1 MK-6302
- 8.4.1.2 Peg G-CSF
- 8.4.1.3 PEG Neutrogena
- 8.4.1.4 Grasustek
- 8.4.1.5 LA-EP2006
- 8.4.1.6 R-TPR-029
- 8.4.1.7 Filgrastim
- 8.4.1.8 PEG-GCSF
- 8.4.1.9 Others
- 8.5 Global Pegfilgrastim Biosimilars Market by Application
- 8.5.1 Market Overview
- 8.5.1.1 Chemotherapy Induced Neutropenia
- 8.5.1.2 Transplantation
- 8.5.1.3 Others
- 8.6 Global Pegfilgrastim Biosimilars Market by Distribution Channel
- 8.6.1 Market Overview
- 8.6.1.1 Hospital Based Pharmacies
- 8.6.1.2 Online Pharmacies
- 8.6.1.3 Retail Pharmacies
- 8.7 Global Pegfilgrastim Biosimilars Market by Region
- 8.7.1 Market Overview
- 8.7.1.1 North America
- 8.7.1.2 Europe
- 8.7.1.3 Asia Pacific
- 8.7.1.4 Latin America
- 8.7.1.5 Middle East and Africa
- 9 North America Pegfilgrastism Biosimilar Market
- 9.1 United States of America
- 9.1.1 Historical Trend (2016-2022)
- 9.1.2 Forecast Trend (2023-2031)
- 9.2 Canada
- 9.2.1 Historical Trend (2016-2022)
- 9.2.2 Forecast Trend (2023-2031)
- 10 Europe Pegfilgrastism Biosimilar Market
- 10.1 United Kingdom
- 10.1.1 Historical Trend (2016-2022)
- 10.1.2 Forecast Trend (2023-2031)
- 10.2 Germany
- 10.2.1 Historical Trend (2016-2022)
- 10.2.2 Forecast Trend (2023-2031)
- 10.3 France
- 10.3.1 Historical Trend (2016-2022)
- 10.3.2 Forecast Trend (2023-2031)
- 10.4 Italy
- 10.4.1 Historical Trend (2016-2022)
- 10.4.2 Forecast Trend (2023-2031)
- 11 Asia Pacific Pegfilgrastism Biosimilar Market
- 11.1 China
- 11.1.1 Historical Trend (2016-2022)
- 11.1.2 Forecast Trend (2023-2031)
- 11.2 Japan
- 11.2.1 Historical Trend (2016-2022)
- 11.2.2 Forecast Trend (2023-2031)
- 11.3 India
- 11.3.1 Historical Trend (2016-2022)
- 11.3.2 Forecast Trend (2023-2031)
- 11.4 ASEAN
- 11.4.1 Historical Trend (2016-2022)
- 11.4.2 Forecast Trend (2023-2031)
- 11.5 Australia
- 11.5.1 Historical Trend (2016-2022)
- 11.5.2 Forecast Trend (2023-2031)
- 12 Latin America Pegfilgrastism Biosimilar Market
- 12.1 Brazil
- 12.1.1 Historical Trend (2016-2022)
- 12.1.2 Forecast Trend (2023-2031)
- 12.2 Argentina
- 12.2.1 Historical Trend (2016-2022)
- 12.2.2 Forecast Trend (2023-2031)
- 12.3 Mexico
- 12.3.1 Historical Trend (2016-2022)
- 12.3.2 Forecast Trend (2023-2031)
- 13 Middle East and Africa Pegfilgrastism Biosimilar Market
- 13.1 Saudi Arabia
- 13.1.1 Historical Trend (2016-2022)
- 13.1.2 Forecast Trend (2023-2031)
- 13.2 United Arab Emirates
- 13.2.1 Historical Trend (2016-2022)
- 13.2.2 Forecast Trend (2023-2031)
- 13.3 Nigeria
- 13.3.1 Historical Trend (2016-2022)
- 13.3.2 Forecast Trend (2023-2031)
- 13.4 South Africa
- 13.4.1 Historical Trend (2016-2022)
- 13.4.2 Forecast Trend (2023-2031)
- 14 Global Pegfilgrastim Biosimilars Market Dynamics
- 14.1 Market Drivers and Constraints
- 14.2 Drug Adoption Parameters
- 14.3 SWOT Analysis
- 14.4 Porter Five Forces Model
- 14.5 Key Demand Indicators
- 14.6 Key Price Indicators
- 14.7 Market Events, Initiatives, and Trends
- 14.8 Value Chain Analysis
- 15 Supplier Landscape
- 15.1 Merck & Co., Inc.
- 15.1.1 Company Overview
- 15.1.2 Product Portfolio
- 15.1.3 Demographic Reach and Achievements
- 15.1.4 Mergers and Acquisitions
- 15.1.5 Certifications
- 15.2 Zydus Lifesciences Limited
- 15.2.1 Company Overview
- 15.2.2 Product Portfolio
- 15.2.3 Demographic Reach and Achievements
- 15.2.4 Mergers and Acquisitions
- 15.2.5 Certifications
- 15.3 Ratiopharm GmbH
- 15.3.1 Company Overview
- 15.3.2 Product Portfolio
- 15.3.3 Demographic Reach and Achievements
- 15.3.4 Mergers and Acquisitions
- 15.3.5 Certifications
- 15.4 Jiangsu Hengrui Pharmaceuticals Co. Ltd
- 15.4.1 Company Overview
- 15.4.2 Product Portfolio
- 15.4.3 Demographic Reach and Achievements
- 15.4.4 Mergers and Acquisitions
- 15.4.5 Certifications
- 15.5 Biocon Limited
- 15.5.1 Company Overview
- 15.5.2 Product Portfolio
- 15.5.3 Demographic Reach and Achievements
- 15.5.4 Mergers and Acquisitions
- 15.5.5 Certifications
- 15.6 Dr. Reddy's Laboratories Ltd
- 15.6.1 Company Overview
- 15.6.2 Product Portfolio
- 15.6.3 Demographic Reach and Achievements
- 15.6.4 Mergers and Acquisitions
- 15.6.5 Certifications
- 15.7 Pfizer Inc.
- 15.7.1 Company Overview
- 15.7.2 Product Portfolio
- 15.7.3 Demographic Reach and Achievements
- 15.7.4 Mergers and Acquisitions
- 15.7.5 Certifications
- 15.8 Emcure Pharmaceuticals Limited
- 15.8.1 Company Overview
- 15.8.2 Product Portfolio
- 15.8.3 Demographic Reach and Achievements
- 15.8.4 Mergers and Acquisitions
- 15.8.5 Certifications
- 15.9 USV Private Limited
- 15.9.1 Company Overview
- 15.9.2 Product Portfolio
- 15.9.3 Demographic Reach and Achievements
- 15.9.4 Mergers and Acquisitions
- 15.9.5 Certifications
- 15.10 Apotex Pty Ltd
- 15.10.1 Company Overview
- 15.10.2 Product Portfolio
- 15.10.3 Demographic Reach and Achievements
- 15.10.4 Mergers and Acquisitions
- 15.10.5 Certifications
- 15.11 Kyowa Kirin Co., Ltd.
- 15.11.1 Company Overview
- 15.11.2 Product Portfolio
- 15.11.3 Demographic Reach and Achievements
- 15.11.4 Mergers and acquisitions
- 15.11.5 Certifications
- 15.12 Lupin Limited
- 15.12.1 Company Overview
- 15.12.2 Product Portfolio
- 15.12.3 Demographic Reach and Achievements
- 15.12.4 Mergers and Acquisitions
- 15.12.5 Certifications
- 16 Pricing Models and Strategies (Additional Insight)
- 16.1 Cost Model
- 16.1.1 Manufacturing Cost Analysis
- 16.1.2 Procurement Cost Analysis
- 16.2 Pricing Strategies
- 16.2.1 Competitor Pricing Analysis
- 16.2.2 Key Assessment of Product Attributes
- 16.2.3 Pricing Benchmark
- 17 Global Pegfilgrastim Biosimilars Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook